Long Chang | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Long Chang | Medicine and Health Sciences | Best Researcher Award

Peking Union Medical College Hospital | China

Dr. Long Chang is an accomplished physician and clinical researcher whose career demonstrates excellence in patient care and significant contributions to hematology. He currently serves as an Attending Physician at the Department of Hematology, Peking Union Medical College Hospital, Beijing, China, building upon his medical training at Peking Union Medical College, Tsinghua University. His research focuses on rare hematologic disorders, particularly myeloproliferative neoplasms and histiocytic diseases, with emphasis on improving diagnostic precision, expanding therapeutic strategies, and enhancing patient outcomes. According to Scopus (Author ID: 57225110413), Dr. Long Chang has authored 39 publications, which have collectively received 165 citations across 152 documents, reflecting the impact of his work, and holds an h-index of 6. He has published influential studies in leading journals including Leukemia, EClinicalMedicine, Oncologist, and Orphanet Journal of Rare Diseases. His work has advanced treatment options for Rosai-Dorfman disease and Langerhans cell histiocytosis while also providing novel insights into gamma heavy chain disease. Notably, his clinical trials have introduced promising approaches such as low-dose cytarabine and novel immunomodulatory therapies, offering alternatives for conditions with limited treatments. Beyond publications, Dr. Long Chang demonstrates commitment to translational medicine by bridging molecular research with patient-centered care. Recognized by peers for his rigor, innovation, and leadership, he has progressed from Resident and Chief Resident to Attending Physician, reflecting both clinical expertise and academic excellence. With impactful contributions influencing practice worldwide, Dr. Long Chang exemplifies the qualities of a dedicated physician-scientist whose work continues to advance the frontiers of hematology.

Profile: Scopus

Featured Publications

  • Chang, L., Zhou, D. B., & Cao, X. X. (2023). Gamma heavy chain disease: A retrospective analysis of 6 cases. Orphanet Journal of Rare Diseases, 18(1), 77.

  • Chang, L., Qiao, B., Cai, H., et al. (2023). Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease. Leukemia, 37(11), 2297–2300.

  • Chang, L., Lang, M., Lin, H., et al. (2024). Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis. Leukemia, 38(4), 803–809.

  • Chang, L., Lang, M., Liu, T., et al. (2024). Lenalidomide and dexamethasone for Rosai-Dorfman disease: A single arm, single center, prospective phase 2 study. EClinicalMedicine, 73, 102685.

  • Chang, L., Cai, H. C., Lang, M., et al. (2024). Liver involvement with Langerhans cell histiocytosis in adults. The Oncologist. Advance online publication.

Andrej Sirek | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Andrej Sirek | Medicine and Health Sciences | Best Researcher Award

University Hospital Basel | Switzerland

Dr. Andrej Sirek is a dedicated Pathology Resident at the University Hospital Basel, Institute of Medical Genetics and Pathology, where he is actively shaping his career at the intersection of clinical diagnostics and medical research. With his educational foundation built in leading European institutions, Dr. Andrej Sirek has developed a strong grounding in medical genetics, histopathology, and laboratory sciences, which now supports his dual role as both clinician and researcher. His residency provides him with exposure to complex pathology cases while also allowing him to engage in research that seeks to bridge genetic profiling and diagnostic pathology, with the long-term aim of contributing to precision medicine and early disease detection. Currently, he has completed one research project and is progressing with another, both expected to yield indexed publications in the near future. Despite being at an early stage of his academic career, his commitment to innovation in pathology has already been recognized with a nomination for the Best Researcher Award. He maintains active membership in several professional organizations, including SGPATH, ÖGPATH, SGZ, and ESP, which strengthens his global collaborations and engagement with the wider pathology community. While he has yet to publish peer-reviewed articles, his ongoing research demonstrates his potential to make impactful contributions to the field. His academic and professional journey underscores the promise of a new generation of clinician-scientists who integrate advanced diagnostic techniques with research innovation to improve patient care. Dr. Andrej Sirek’s trajectory highlights his dedication, scholarly potential, and commitment to excellence in pathology and medical genetics.

Profile: ORCID

Featured Publications

Dr. Andrej Sirek has contributed to impactful research in pathology, focusing on diagnostic innovations, tumor biology, and clinicopathological correlations. Key recent publications include:

Sirek, A., Hench, I. B., Hench, J., Alborelli, I., Gross, M. W., Jakscha, J., Schaller, P., Nagel, G., Baumhoer, D., & Tzankov, A. (2025). Recurrent clonal radiotherapy-associated fibroepithelial polyp of the pharynx: Do low grade radiogenic stromal tumours exist? Case report.

Sobottka, B., Vetter, V., Banaei-Esfahani, A., Nowak, M., Lorch, A., Sirek, A., Mertz, K. D., Brunelli, M., Berthold, D., de Leval, L., et al. (2024). Immune phenotype-genotype associations in primary clear cell renal cell carcinoma and matched metastatic tissue.